3D-QSAR CoMFA study on imidazolinergic I2 ligands:: A significant model through a combined exploration of structural diversity and methodology

被引:48
作者
Baurin, N
Vangrevelinghe, E
Morin-Allory, L
Mérour, JY
Renard, P
Payard, M
Guillaumet, G
Marot, C
机构
[1] Univ Orleans, CNRS, Inst Chim Organ & Analyt, F-45067 Orleans 2, France
[2] ADIR & Cie, F-92415 Courbevoie, France
[3] Univ Toulouse 3, Fac Pharm Toulouse, Chim Therapeut Lab, F-31400 Toulouse, France
关键词
D O I
10.1021/jm991124t
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Displaying an unprecedented structural diversity, 119 I-2 ligands, and their pK(i) values, were collected and submitted to a comparative molecular fields analysis (CoMFA) study. They were discerned into three structural subsets (A, B, C), to explore the I-2 3D-QSARs from finite structural systems (A, B, C) to more complex ones (AB, AC, BC, ABC). In addition, various key steps of the CoMFA methology were explored. The applied method used two pharmacophore templates and seven molecular field combinations (electrostatic, lipophilic, steric), as well as eight alignment methods (two point-by-point and six similarity-based variations). That way, 644 CoMFA models were obtained and further selected according to their predictive ability through two filters. The first filter was mainly based on the q(2), which internally evaluates the predictive ability from the training set. For the second filter, the predictive ability was externally evaluated through the prediction of test sets. Finally, one model was extracted from the whole data as the best. Indeed, it combines three features of upmost importance for the further design of ligands endowed with high It affinity: structural diversity (n = 73), robustness (N = 9, r(2) = 0.96, s = 0.28, F = 148), and a great fully assessed predictive ability (q(2) = 0.50, r(2) (test set) = 0.81, n(test set) = 46). On the basis of structural data and CoMFA isocontours, some elements of the It tridimensional pharmacophore are also suggested.
引用
收藏
页码:1109 / 1122
页数:14
相关论文
共 38 条
[1]   APPLICATION OF MOLECULAR LIPOPHILICITY POTENTIAL TO A SERIES OF BETA-ADRENOLYTIC AMINES [J].
AUDRY, E ;
DUBOST, JP ;
DALLET, P ;
LANGLOIS, MH ;
COLLETER, JC .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1989, 24 (02) :155-161
[2]   Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands [J].
Boronat, MA ;
Olmos, G ;
García-Sevilla, JA .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (01) :175-185
[3]  
BOUSQUET P, 1984, J PHARMACOL EXP THER, V230, P232
[4]   LCAO-MO SIMILARITY MEASURES AND TAXONOMY [J].
CARBO, R ;
DOMINGO, L .
INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY, 1987, 32 (04) :517-545
[5]   Evolution of the human RH (rhesus) blood group genes: A 50 year old prediction (partially) fulfilled [J].
Carritt, B ;
Kemp, TJ ;
Poulter, M .
HUMAN MOLECULAR GENETICS, 1997, 6 (06) :843-850
[6]   Clonidine-displacing substance and irs putative role in control of insulin secretion: A minireview [J].
Chan, SLF .
GENERAL PHARMACOLOGY, 1998, 31 (04) :525-529
[7]   Potential mechanisms of moxonidine-induced ocular hypotension: Role of norepinephrine [J].
Chu, TC ;
Socci, RR ;
Ogidigben, MJ ;
Potter, DE .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 1997, 13 (06) :489-496
[8]   3-amino-3,4-dihydro-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents .2. Synthesis and quantitative structure-activity relationship studies of spiro[pyrrolidine- and piperidine-2,3'(2'H)-benzopyrans] [J].
Comoy, C ;
Marot, C ;
Podona, T ;
Baudin, ML ;
MorinAllory, L ;
Guillaumet, G ;
Pfeiffer, B ;
Caignard, DH ;
Renard, P ;
Rettori, MC ;
Adam, G ;
GuardiolaLemaitre, B .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (21) :4285-4298
[9]   COMPARATIVE MOLECULAR-FIELD ANALYSIS (COMFA) .1. EFFECT OF SHAPE ON BINDING OF STEROIDS TO CARRIER PROTEINS [J].
CRAMER, RD ;
PATTERSON, DE ;
BUNCE, JD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1988, 110 (18) :5959-5967
[10]  
Ernsberger P, 1999, J PHARMACOL EXP THER, V288, P139